Afatinib (Giotrif®) : The 1st choice in 1st-line

Afatinib: The 1st line choice in sequential therapy of NSCLC

 
 

First-line treatment with AFATINIB associated with longer OS in patients with EGFR mutation positive NSCLC. RWE from Chen Kung University, Taiwan

Document ID: PC-VN-101788

13/10/2021

Author: Boehringer Ingelheim

123,000
Views

100k 340

NHỮNG NỘI DUNG LIÊN QUAN

 
PC-VN-101788
Production date: October 2021